CIK 0001434316 · Non-accelerated filer<br>Smaller reporting company
FATE THERAPEUTICS INC
Sign in to watch- Ticker
- FATE
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Entity type
- operating
- EIN
- 651311552
- Phone
- 858.875.1803
- Business address
- 12278 SCRIPPS SUMMIT DRIVE, SAN DIEGO, CA, 92131
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $13,525
- in 1 filing
Net −$13,525. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2023-04-14 | Redmile Group, LLC Director | Sale | −302,339 | $5.84 | $1.8M | 12,833,419 |
| 2023-04-14 | Redmile Group, LLC Director | Other disposition | −5,492,385 | $5.84 | $32.1M | 12,833,419 |
| 2023-04-14 | Redmile Group, LLC Director | Other acquisition | +5,492,385 | $5.84 | $32.1M | 12,833,419 |
| 2023-04-14 | Redmile Group, LLC Director | Purchase | +25,700 | $6.00 | $154K | 12,859,119 |
| 2023-04-14 | Redmile Group, LLC Director | Other disposition · Class A Convertible Preferred Stock | −45,752 | $29.20 | $1.3M | 2,761,108 |
| 2023-04-14 | Redmile Group, LLC Director | Other acquisition · Class A Convertible Preferred Stock | +45,752 | $29.20 | $1.3M | 2,761,108 |
| 2023-04-14 | Redmile Group, LLC Director | Other disposition · Pre-Funded Warrants to Purchase Common Stock | −54,960 | $5.84 | $321K | 257,310 |
| 2023-04-14 | Redmile Group, LLC Director | Other acquisition · Pre-Funded Warrants to Purchase Common Stock | +54,960 | $5.84 | $321K | 257,310 |
| 2023-04-14 | Redmile Group, LLC Director | Other disposition · Cash-settled Swaps | −550,000 | $5.84 | $3.2M | 559,100 |
| 2023-04-14 | Redmile Group, LLC Director | Other acquisition · Cash-settled Swaps | +550,000 | $5.84 | $3.2M | 559,100 |
| 2023-04-13 | Redmile Group, LLC Director | Conversion | +167,205 | 13,135,758 | ||
| 2023-04-13 | Redmile Group, LLC Director | Conversion · Class A Convertible Preferred Stock | −33,441 | 2,761,108 | ||
| 2023-02-06 | Wolchko J Scott President and CEO | Grant or award · Stock Option (Right to Buy) | +500,000 | 500,000 | ||
| 2023-02-06 | Valamehr Bahram Chief R&D Officer | Grant or award · Stock Option (Right to Buy) | +450,000 | 450,000 | ||
| 2023-02-06 | TAHL CINDY General Counsel and Secretary | Grant or award · Stock Option (Right to Buy) | +425,000 | 425,000 | ||
| 2023-02-06 | Powl Brian T. Chief Commercial Officer | Grant or award · Stock Option (Right to Buy) | +425,000 | 425,000 | ||
| 2023-02-06 | Dulac Edward J III Chief Financial Officer | Grant or award · Stock Option (Right to Buy) | +425,000 | 425,000 | ||
| 2023-02-06 | Chu Yu-Waye Chief Medical Officer | Grant or award · Stock Option (Right to Buy) | +425,000 | 425,000 | ||
| 2023-01-19 | MENDLEIN JOHN Director | Option exercise | +28,461 | $1.37 | $39K | 311,231 |
| 2023-01-19 | MENDLEIN JOHN Director | Option exercise · Stock Option (Right to Buy) | +28,461 | 0 |
Page 7 of 8 · 144 trades